Equities Analysts Set Expectations for ENTA FY2026 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the biotechnology company will post earnings per share of ($2.49) for the year, down from their prior forecast of ($2.18). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q4 2026 earnings at ($0.95) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($3.37) EPS, FY2029 earnings at ($2.55) EPS and FY2030 earnings at ($2.17) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.61%.

A number of other brokerages have also recently commented on ENTA. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Trading Down 0.1%

ENTA opened at $13.50 on Thursday. The company has a market cap of $392.58 million, a price-to-earnings ratio of -5.60 and a beta of 0.98. The stock has a fifty day simple moving average of $13.18 and a two-hundred day simple moving average of $13.44. Enanta Pharmaceuticals has a 12-month low of $6.60 and a 12-month high of $17.15.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth $32,000. Seven Fleet Capital Management LP bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $36,000. Strs Ohio purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Clearstead Trust LLC bought a new position in Enanta Pharmaceuticals in the 2nd quarter worth about $74,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.